The leukemia therapeutics treatment market valuation is USD 15,246.7 million in 2023. In 2022, the value was USD 14,504.8 million. The market is predicted to grow at a healthy CAGR of 7.1% from 2023 to 2033. The valuation of the leukemia therapeutics treatment market is anticipated to reach USD 30,318.5 million by 2033.
Production Analysis of the Leukemia Therapeutics Treatment Market
| Attributes | Details |
|---|---|
| Leukemia Therapeutics Treatment Market Value for 2023 | USD 15,246.7 million |
| Projected Market Value for 2033 | USD 30,318.5 million |
| Value-based CAGR of Market for 2023 to 2033 | 7.1% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The leukemia therapeutics treatment market was valued at USD 12034.0 million in 2017. The market progressed at a sluggish CAGR of 3.8% over the historical period from 2017 to 2022.
Due to the pandemic, an increasing number of resources were diverted towards Covid-19 treatment. As a result, leukemia therapeutics treatment suffered during the historical period. Nonetheless, the progress in different types of treatment and medicines continued. At the end of the historical period in 2022, the value of the leukemia therapeutics treatment market had reached USD 14,504.8 million.
| Market Value (2017) | USD 12,034.0 million |
|---|---|
| Historical CAGR (2017 to 2022) | 3.8% |
| Historical Market Valuation (2022) | USD 14,504.8 million |
The leukemia therapeutics treatment market is estimated to be USD 15,246.7 million in size in 2023. The progress of the market is predicted to be promising, with a CAGR of 7.1% over the forecast period.
The progress in the forecast period is set to outpace the progress in the historical period. As companies keep innovating with the help of technology, leukemia treatment is getting more effective. The cases of leukemia are also not slated to slow down over the forecast period, necessitating treatment for the disease.
Medical care is increasingly looked upon positively. Thus, leukemia therapeutics treatment is widely accepted to combat the disease. By 2033, the valuation of the leukemia therapeutics treatment market is expected to be USD 30,318.5 million.
Principal Consultant
The leukemia therapeutics treatment market can be divided into four segments: treatment, molecule, mode of administration, and indication. By looking at the segments, the inclinations of the consumers become clear. The types of treatment and the way the consumers choose to receive treatment can also be seen.
Targeted drugs & immunotherapy are the preferred mode of treatment for patients. In 2022, targeted drugs & immunotherapy accounted for 57.2% of the market share by treatment.
Several drugs, such as Gleevec, Bosulif, and Sprycel, are in the leukemia treatment market. Many drugs are also under trial, with the Revumenib drug showing positive results while testing. Thus, drugs and immunotherapy are popular treatments. Chemotherapy is the preferred treatment method highly sought by patients in increasing numbers.
| Attributes | Details |
|---|---|
| Top Treatment | Targeted Drugs & Immunotherapy |
| Market Share in 2022 | 57.2% |
Small molecules are the most commonly used type of molecule in leukemia therapeutics treatment. In 2022, small molecules accounted for 55.6% of the market share by molecule.
The adoption of small molecules through inhibitors has been effective in leukemia treatment. Further, small molecule treatment has also led to fewer side effects in patients.
| Attributes | Details |
|---|---|
| Top Molecule | Small Molecule |
| Market Share in 2022 | 55.6% |
Injecting drugs is the preferred mode of administration for patients. In 2022, injectable treatment accounted for 61.7% of the market share by mode of administration.
Injections are commonly believed to act faster than doses of oral medicine. In leukemia treatment, consumers also opt for injectables as a mode for faster results.
| Attributes | Details |
|---|---|
| Top Mode of Administration | Injectable |
| Market Share in 2022 | 61.7% |
Chronic myeloid leukemia patients (CML) are the leading leukemia therapeutics treatment market. In 2022, the CML contributed to 43.2% of the market share by indication.
Effective CML treatment has drastically improved the survival rate. About 90% of the patients of CML are now expected to pull through the disease. Thus, the treatment of CML has earned an enhanced reputation.
| Attributes | Details |
|---|---|
| Top Indication | Chronic Myeloid Leukemia (CML) |
| Market Share in 2022 | 43.2% |
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
North America and Europe account for a large share of the market. In 2022, North America and Europe contributed 37.6% and 25.6% of the market share, respectively. The United States, in particular, held 33.3% of the global market share.
Countries in the Asia Pacific, like China, India, Japan, and South Korea, are slated to show substantial growth in the market over the coming years. Rapidly increasing population and economic development are leading factors in the growth of the market in the Asia Pacific region.
| Countries | CAGR |
|---|---|
| South Korea | 10.0% |
| China | 10.6% |
| Japan | 9.6% |
| India | 8.6% |
| Australia | 6.9% |
China is predicted to show incredible growth in the leukemia therapeutics treatment market during the forecast period. The Chinese market is expected to grow at a stellar CAGR of 10.6% through 2033.
Players in the Chinese market are increasingly focused on breakthroughs. Therefore, the nature of leukemia treatment in China is getting modernized. For example, in January 2022, Chinese scientists found a potential treatment for leukemia with the infusion of nanoparticles into the bloodstream.
South Korea is another Asian country with significant potential for the market. The South Korean market is forecasted to grow at an impressive CAGR of 10.0% over the forecast period.
Impressive healthcare facilities in South Korea attract even people from outside the country. Cancer treatment and research are also on the up in South Korea. Some expenses of cancer treatment are reimbursable in the country. Thus, the market is well-positioned in South Korea.
The market is expected to thrive in Japan as well. The Japanese market is expected to grow at a sturdy CAGR of 9.6% through 2033.
The average age in Japan is rising rapidly. Elderly people are prone to leukemia and form a huge section of the customer base for the leukemia therapeutics treatment industry. Therefore, Japan is rife with opportunities for the market.
Heavy investment is needed for innovations and breakthroughs in leukemia treatment. Thus, large companies with financial capacity hold a strong position in the market. However, with the aid of government and private funding, operations on a smaller scale also have scope.
Companies in the market have to wait for approvals to launch products into the market. Nonetheless, the players in the market are focused on having a wide range of products to treat different types of leukemia.
Recent Developments in the Leukemia Therapeutics Treatment Market
The leukemia therapeutics treatment market valuation is USD 15,246.7 million in 2023.
The market size of leukemia therapeutics treatment is predicted to reach USD 30,318.5 million by 2033.
Increasing cases of leukemia and a rise in the global aging population are stimulating the market demand.
The leukemia therapeutics treatment market is expected to progress at a CAGR of 7.1% from 2023 to 2033.
Ambit Biosciences Corporation, Biogen Idec, Inc., Ariad Pharmaceuticals, Inc., and Bristol-Myers Squibb are some of the prominent companies in the market.
1. Executive Summary 2. Market Overview 3. Market Background 4. Global Industry Analysis and Outlook 2018 to 2022 and Forecast, 2023 to 2033 5. Global Industry Analysis and Outlook 2018 to 2022 and Forecast 2023 to 2033, By Treatment Type 5.1. Targeted Drugs 5.2. Chemotherapy 6. Global Industry Analysis and Outlook 2018 to 2022 and Forecast 2023 to 2033, By Molecule Type 6.1. Biologics 6.2. Small Molecules 7. Global Industry Analysis and Outlook 2018 to 2022 and Forecast 2023 to 2033, By Mode of Administration 7.1. Injectable 7.2. Oral 8. Global Industry Analysis and Outlook 2018 to 2022 and Forecast 2023 to 2033, By Type 8.1. AML 8.2. CML 8.3. ALL 8.4. CLL 9. Global Industry Analysis and Outlook 2018 to 2022 and Forecast 2023 to 2033, By Region 9.1. North America 9.2. Latin America 9.3. Western Europe 9.4. Eastern Europe 9.5. South Asia and Pacific 9.6. East Asia 9.7. Middle East and Africa 10. North America Industry Analysis and Outlook 2018 to 2022 and Forecast 2023 to 2033, By Country 11. Latin America Industry Analysis and Outlook 2018 to 2022 and Forecast 2023 to 2033, By Country 12. Western Europe Industry Analysis and Outlook 2018 to 2022 and Forecast 2023 to 2033, By Country 13. Eastern Europe Industry Analysis and Outlook 2018 to 2022 and Forecast 2023 to 2033, By Country 14. South Asia and Pacific Industry Analysis and Outlook 2018 to 2022 and Forecast 2023 to 2033, By Country 15. East Asia Industry Analysis and Outlook 2018 to 2022 and Forecast 2023 to 2033, By Country 16. Middle East and Africa Industry Analysis and Outlook 2018 to 2022 and Forecast 2023 to 2033, By Country 17. Key Countries Industry Analysis and Outlook 18. Market Structure Analysis 19. Competition Analysis 19.1. Novartis International AG 19.2. GlaxoSmithKline Pharmaceuticals Limited 19.3. Roche 19.4. Bristol-Myers Squibb 19.5. Genmab A/S 19.6. Celgene Corporation 19.7. Biogen 19.8. Pfizer 19.9. Ambit Biosciences Corporation 19.10. Ariad Pharmaceuticals, Inc 20. Assumptions & Acronyms Used 21. Research Methodology
Explore Healthcare Insights
View Reports
Leukemia Therapeutics Treatment Market
